We're committed to increasing patient access to quality, affordable medicines. One of the ways we’re working to achieve this goal is our focus on biosimilar medicines. Biosimilars can fill an urgent, unmet patient need for more affordable alternatives to existing branded biologic therapies. Biosimilar medicines are approved by regulatory authorities as highly similar to the originally approved brand version with no clinically meaningful differences in safety or efficacy.